For patients with moderate to severe eosinophilic asthma or oral corticosteroid (OCS)-dependent asthma and inadequate disease control, the decision to add biologic therapy is based on the patient’s ...

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations compared with albuterol alone for people with normally mild asthma, the phase ...

Thanks to improved treatments, many people with asthma live good lives. However, for a smaller group—those with severe asthma ...

Please provide your email address to receive an email when new articles are posted on . Patients with asthma saw a 23% reduction in FeNO with treatment. Most adverse events were mild, with no serious ...

Blood eosinophil count and fractional exhaled nitric oxide (FeNO) play an important role in selecting biological therapies for severe asthma. This analysis of patient-level data pooled across 22 ...

As-needed use of albuterol–budesonide has been shown to result in a significantly lower risk of severe asthma exacerbation than as-needed use of albuterol alone among patients with moderate-to-severe ...

Please provide your email address to receive an email when new articles are posted on . High FeNO levels indicate exacerbation and lung function risks. Most patients with high FeNO levels also had ...

(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) announced a major update to the U.S. prescribing information for AIRSUPRA, following new clinical evidence from the BATURA study. This Phase IIIb ...

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track ...

Good morning, and welcome to Apogee Therapeutics' Conference Call [Operator Instructions] Please be advised that this call is being recorded at the company's request. I will now turn the call over to ...